##  [Novartis reports new Phase III data showing secukinumab (AIN457) improved moderate-to-severe plaque psoriasis in patients](/us-en/news/media-releases/novartis-reports-new-phase-iii-data-showing-secukinumab-ain457-improved-moderate-severe-plaque-psoriasis-patients-0 "Novartis reports new Phase III data showing secukinumab (AIN457) improved moderate-to-severe plaque psoriasis in patients") 

  Mar 22, 2014